nach oben

Erschienen in:

01.10.2019 | Clinical study

Ibrutinib-associated cardiovascular adverse events

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Ibrutinib is associated cardiovascular adverse drug reactions (CV-ADR) which are potentially fatal, according to findings of an analysis of data from the WHO pharmacovigilance database published in the Journal of the American College of Cardiology.¹ …

lower limit of 95% credibility interval

Salem J-E. Cardiovascular Toxicities Associated With Ibrutinib. Journal of the American College of Cardiology 74: 1667-1678, No. 13, 1 Oct 2019. Available from: URL: http://dx.doi.org/10.1016/j.jacc.2019.07.056

Bergler-Klein J. Real-Life Insight Into Ibrutinib Cardiovascular Events: Defining the Loose Ends. Journal of the American College of Cardiology 74: 1679-1681, No. 13, 1 Oct 2019. Available from: URL: https://doi.org/10.1016/j.jacc.2019.07.057

Titel: Ibrutinib-associated cardiovascular adverse events
Publikationsdatum: 01.10.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-68763-y

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Ibrutinib-associated cardiovascular adverse events

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Botulinum toxin-A

Dabigatran etexilate/rivaroxaban

Olodaterol/tiotropium bromide

Melphalan

Digoxin

Dabigatran-etexilate